drugset / Trial / NCT06850727

Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis

NCT06850727

Phase 2 Recruiting 57 enrolled Odyssey Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the clinical efficacy and safety of OD-07656 in participants with moderately to severely active ulcerative colitis (UC). In addition, the study will evaluate the potential of OD-07656 to enhance the therapeutic benefit of vedolizumab when given after OD-07656.

Timeline

Start
2025-06-02
Primary completion
2026-04
Completion
2026-11

Drugs

EvaluationDrugModalityDoseRoute
Subject OD-07656 Unknown Oral
Subject Vedolizumab Monoclonal antibody Oral

Indications